Economic Evaluation in Clinical Trials (Handbooks in Health Economic Evaluation)

De (autor) , , ,
Notă GoodReads:
en Limba Engleză Paperback – 02 Oct 2014
It is becoming increasingly important to examine the relationship between the outcomes of a clinical trial and the costs of the medical therapy under study. The results of such analysis can affect reimbursement decisions for new medical technologies, drugs, devices or diagnostics. It can aid
companies seeking to make claims about the cost-effectiveness of their product, as well as allowing early consideration of the economic value of therapies which may be important to improving initial adoption decisions. It is also vital for addressing the requirements of regulatory bodies.

Economic Evaluation in Clinical Trials provides practical advice on how to conduct cost-effectiveness analyses in controlled trials of medical therapies. This new edition has been extensively rewritten and revised; topics discussed range from design issues such as the types of services that should
be measured and price weights, to assessment of quality-adjusted life years. Illustrative materials, case histories and worked examples are included to encourage the reader to apply the methods discussed. These exercises are supported with datasets, programmes and solutions made available online.

Citește tot Restrânge

Din seria Handbooks in Health Economic Evaluation

Preț: 31911 lei

Preț vechi: 33590 lei

Puncte Express: 479

Preț estimativ în valută:
6175 7267$ 5290£

Carte disponibilă

Livrare economică 12-16 august

Preluare comenzi: 021 569.72.76


ISBN-13: 9780199685028
ISBN-10: 0199685029
Pagini: 272
Dimensiuni: 156 x 233 x 16 mm
Greutate: 0.4 kg
Ediția: Revised
Editura: Oxford University Press
Colecția OUP Oxford
Seria Handbooks in Health Economic Evaluation

Locul publicării: Oxford, United Kingdom


It is a great resource and an extremely practical guide.

Notă biografică

Henry A. Glick, Ph.D., received an M.A. and Ph.D. in Public Policy Analysis from the University of Pennsylvania. He has more than 25 years of experience conducting economic assessments of medical therapies. He specializes in economic evaluations conducted as part of clinical trials. Henry served on the Randomized Clinical Trial-Cost Effectiveness Analysis (RCT-CEA) Task Force and the Task Force on Good Research Practices on Transferability of Economic Data in HealthTechnology Assessment, both chartered by the International Society of Pharmaceutical Outcomes Research (ISPOR) to develop guidance documents related to these issues.Daniel Polsky, Ph.D., has been on the faculty at the University of Pennsylvania since 1996. He is the Executive Director of the Leonard Davis Institute of Health Economics, Professor of Medicine in the Perelman School of Medicine and the Robert D. Eilers Professor of Health Care Management in the Wharton School. He currently serves on the Congressional Budget Office's Panel of Health Advisers and he was the Senior Economist on health issues at the President's Council of Economic Advisers in2007-08. His research areas include access to health care, workforce, and economic evaluation of medical and behavioral health interventions.Seema Sonnad, Ph.D., is interested in how patients, physicians and health systems use (or fail to use) evidence when making decisions about new technology. She has been involved in collaborative work leading to over 130 published papers and after being Director of Outcomes Research in departments of surgery for over 10 years, is now Director of Health Services Research for the Value Institute at Christiana Care Health System. She continues to work collaboratively with physicians to understandhow changing practice impacts care and how to incorporate best evidence into care decisions.Dr. Jalpa Doshi's research focuses on economic and outcomes assessments of medication use and adherence in vulnerable patient populations such as the elderly, disabled, and chronically ill using observational as well as randomized trial data. She is regularly invited to teach methodology courses and workshops on cost-effectiveness analyses in randomized trials and analytic techniques to examine health care cost data at scientific meetings. She has served on the International Society ofPharmaceutical Outcomes Research (ISPOR) Task Force Quality Improvement in Cost Effectiveness Research. She currently serves as co-editor of the Value in Health Journal.